Pharmaceutical Technology

MAY 29, 2023

The global pharmaceutical industry experienced a 17% rise in company filings mentions of blockchain in Q1 2023 compared with the previous quarter, with the highest share accounted for by Bayer, according to GlobalData’s analysis of over 60 pharmaceutical company filings. Starting at 100 in 2020, an index over 100 is more positive.

Marketing 130

Marketing Medicine 130

Pharmaceutical Technology

JUNE 6, 2023

The global pharma industry experienced an 11% rise in social media posts on regenerative medicine in Q1 2023 compared with the previous quarter, with the highest share accounted for Pfizer, according to GlobalData’s analysis of social media posts. Buy the report here.

Medicine 100

Medicine Drugs Research 100

Drug Discovery World

JANUARY 10, 2024

The biotech market is heading to recovery in 2024, following a marked downturn in investment in 2022 and 2023, according to healthcare industry professionals. GlobalData spoke to 115 healthcare industry professionals in November 2023.

Marketing 113

Marketing Drugs Development Research 113

Pharmaceutical Technology

JULY 21, 2022

Listed below are the key technology trends impacting the ESG performance in the healthcare sector, as identified by GlobalData. The healthcare industry is vulnerable to cyberattacks due to the amount of valuable and sensitive data it produces. Artificial intelligence (AI). Cybersecurity and ESG.

FDA Approval 245

FDA Approval Pharma Companies Drugs Clinical Trials 245

Pharmaceutical Technology

JULY 19, 2022

All aspects of environmental, social, and governance (ESG) are important, and in the healthcare industry, companies must excel across all three. Listed below are the impact of ESG on healthcare, as identified by GlobalData. The post ESG Top Trends: Healthcare ESG Impact appeared first on Pharmaceutical Technology.

Medicine 162

Medicine Manufacturing Vaccination Vaccine 162

Pharmaceutical Technology

FEBRUARY 28, 2023

According to GlobalData, Phase I drugs for Melanoma have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KFA-115’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Generic Pharmaceutical 172

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 172

Pharmaceutical Technology

FEBRUARY 24, 2023

According to GlobalData, Phase III drugs for Type 2 Diabetes have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (LAI-287 + semaglutide)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Insulin 182

Insulin Hormones Drugs Clinical Trials 182

Pharmaceutical Technology

MAY 31, 2023

According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ZNA-1041’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

In-Vitro 130

In-Vitro Clinical Trials Clinical Trials Drugs 130

Pharmaceutical Technology

MAY 9, 2023

The key social themes, commitment details of leading companies to social responsibility, and discussions and hiring activity for social responsibility in Healthcare and 15 other key sectors are covered in GlobalData’s Social Responsibility Trends by Sector – Thematic Intelligence report. Buy the report here.

113

113

Pharmaceutical Technology

MAY 29, 2023

The global pharmaceutical industry experienced a 24% drop in company filings mentions of regenerative medicine in Q1 2023 compared with the previous quarter, with the highest share accounted for by Sarepta Therapeutics with 20% year-on-year decrease, according to GlobalData’s analysis of over 578 pharmaceutical company filings.

Medicine 100

Medicine Research 100

Pharmaceutical Technology

MAY 9, 2023

The key social themes, commitment details of leading companies to social responsibility, and discussions and hiring activity for social responsibility in Healthcare and 15 other key sectors are covered in GlobalData’s Social Responsibility Trends by Sector – Thematic Intelligence report. Buy the report here.

100

100

Pharmaceutical Technology

NOVEMBER 22, 2022

Drug shortages continue to affect medical care in healthcare systems, and experts tell us that supply bottlenecks for cardiovascular drugs are particularly concerning. All this, and the latest pharma industry news , comment, data, and analysis from GlobalData. Click here to view the latest issue of Pharmaceutical Technology Focus.

Regulation 233

Regulation Drugs 233

Pharmaceutical Technology

APRIL 3, 2023

But while the pandemic hampered access to health care services, it also led to accelerated demand for digital health technologies that enabled women to access remote care during lockdowns, said Wafaa Hasan, GlobalData’s healthcare analyst at a Femtech-centric webinar held on March 30.

Regulation 130

Regulation Compliance Clinical Trials Clinical Trials 130

Pharmaceutical Technology

MARCH 2, 2023

According to GlobalData, Phase I drugs for Relapsed Acute Myeloid Leukemia have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how QN-023a’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Gene Editing 100

Gene Editing Genetic Engineering Engineer Clinical Trials 100

Pharmaceutical Technology

MARCH 22, 2023

Healthcare providers are under pressure to address the growing issue of substance use disorders. According to GlobalData’s Medical Device Pipeline Analytics, there are 61 products in development for treating substance abuse disorders classed as healthcare IT.

FDA Approval 130

FDA Approval Production Compliance Clinical Trials 130

Pharmaceutical Technology

MARCH 2, 2023

According to GlobalData, Phase I drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Hangzhou Qihan Biotechnology overview Hangzhou Qihan Biotechnology is a healthcare company. Buy the report here.

Gene Editing 100

Gene Editing Clinical Trials Clinical Trials Genetics 100

Pharmaceutical Technology

JULY 21, 2022

As part of ESG (Environmental, Social, and Governance), the social good delivered by robust healthcare systems are at the core of healthy populations. The Covid-19 pandemic has demonstrated how vital patient access to quality and affordable healthcare is for patients all over the world. Climate change and ESG.

Pharma Companies 130

Pharma Companies Clinical Trials Clinical Trials Drugs 130

Pharmaceutical Technology

JULY 28, 2022

While all three agents are currently undergoing Phase III trials, GlobalData expects Eli Lilly’s mirikizumab to be the first IL-23-specific inhibitor to be approved for this indication. GlobalData expects regulatory approval of mirikizumab for UC in the US and European Union (EU) next year.

Trials 246

Trials Marketing RNA Development 246

Pharmaceutical Technology

APRIL 13, 2023

Following the increased use of telemedicine during the Covid-19 pandemic, the potential of digital technologies in communication, data collection, and analysis has become increasingly realised by patients, healthcare systems, and clinical trial sponsors.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Dermatology 130

Pharmaceutical Technology

FEBRUARY 28, 2023

According to GlobalData, Phase I drugs for Malignant Mesothelioma have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KFA-115’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 20, 2023

According to GlobalData, Phase II drugs for Systemic Sclerosis (Scleroderma) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BI-685509’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Production 100

Production Manufacturing Clinical Trials Clinical Trials 100

Pharmaceutical Technology

JUNE 5, 2023

According to GlobalData, Phase I drugs for Hypopharyngeal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BI-765063 LoA Report. Buy the report here.

Production 100

Production Manufacturing Drugs Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 28, 2023

According to GlobalData, Phase III drugs for Paroxysmal Nocturnal Hemoglobinuria have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Paroxysmal Nocturnal Hemoglobinuria. Buy the report here.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 28, 2023

According to GlobalData, Phase III drugs for Glomerulonephritis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Iptacopan hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

DECEMBER 7, 2022

On 29 November, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) warned of some new and potentially serious eye-related side effects associated with Dupixent, an interleukin (IL)-4/13 inhibitor drug used in the treatment of numerous allergic indications such as atopic dermatitis, asthma and nasal polyps.

Production 162

Production Regulation Clinical Trials Clinical Trials 162

Pharmaceutical Technology

MARCH 1, 2023

According to GlobalData, Phase I drugs for Neuroendocrine Tumors have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nedisertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

According to GlobalData, Phase I drugs for Head And Neck Cancer Squamous Cell Carcinoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nedisertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

JULY 28, 2022

Despite this, some key opinion leaders (KOLs) interviewed by GlobalData argued that LAIs should be prescribed as soon as possible, following first-episode psychosis or during early-stage schizophrenia. GlobalData forecasts that it will launch in the US and 5EU next year.

Nurses 246

Nurses Production Pharmacy Marketing 246

Pharmaceutical Technology

MAY 31, 2023

More than half (54%) of the surveyed healthcare industry professionals indicated that their sentiment towards Brexit had become more negative. A Brexit survey conducted previously by GlobalData in 2021 found that the majority (60%) of the respondents had a more neutral sentiment towards Brexit at that point.

Life Science 55

Life Science Manufacturing Regulation Medicine 55

Pharmaceutical Technology

OCTOBER 26, 2022

On October 6, in a GlobalData webinar, experts tried to answer the question ‘ Is Pharma at an ESG turning point?’ , revealing a multitude of diverse strategies for pharmaceutical companies to remain conscious of their global impacts. GlobalData is the parent company of Pharmaceutical Technology. Health disparities today.

Clinical Trials 162

Clinical Trials Clinical Trials Trials Life Science 162

Pharmaceutical Technology

JUNE 5, 2023

According to GlobalData, Phase II drugs for Pancreatic Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pralsetinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

In-Vitro 100

In-Vitro Drugs Clinical Trials Clinical Trials 100

Pharmaceutical Technology

NOVEMBER 25, 2022

The global pharmaceutical industry experienced a 30% rise in new job postings related to cybersecurity in Q3 2022 compared with the previous quarter, according to GlobalData’s Jobs Analytics. This compares to a 30% increase in the previous quarter and a 70% increase versus Q3 2021.

Nurses 100

Nurses Development 100

Pharmaceutical Technology

NOVEMBER 25, 2022

The global pharmaceutical industry experienced a 7% drop in new job postings related to artificial intelligence in Q3 2022 compared with the previous quarter, according to GlobalData’s Jobs Analytics. This compares to a 7% increase in the previous quarter and a 63% increase versus Q3 2021.

Scientist 100

Scientist Development 100

Pharmaceutical Technology

FEBRUARY 24, 2023

According to Globaldata, it is involved in 10 clinical trials, of which 4 were completed, 5 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Retatrutide’s valuation in its risk-adjusted NPV model (rNPV). It is a new molecular entity.

Sales 113

Sales Production Clinical Trials Clinical Trials 113

Pharmaceutical Technology

JULY 25, 2022

The COVID-19 pandemic triggered significant changes to the way healthcare operates. According to Tom Lenaerts, Head of Global Process Engineering at Datwyler, this transformation will reshape the entire healthcare ecosystem. Many organizations are busy planning or executing digital strategies, and the supply chain is no exception.

Engineer 286

Engineer Packaging Packaging Production 286

Pharmaceutical Technology

MAY 16, 2023

UniQure is selling a part of its royalty rights to the haemophilia B gene therapy Hemgenix (etranacogene dezaparvovec) to HealthCare Royalty and Sagard Healthcare for a gross purchase price of up to $400 million dollars. HealthCare Royalty is a royalty acquisition company. HealthCare Royalty is a royalty acquisition company.

Gene Therapy 130

Gene Therapy Gene Sales Development 130

XTalks

APRIL 19, 2024

According to GlobalData , the global AI in healthcare market was valued at $81.3 Current leaders in the CT imaging market include Philips, GE HealthCare and Siemens. According to GlobalData, Siemens and GE HealthCare lead with 33.5 According to GlobalData, Siemens and GE HealthCare lead with 33.5

Marketing 52

Marketing Radiology Development Manufacturing 52